M3-Brigade Acquisition Corp. II (NYSE:MBAC) announced this afternoon that it has entered into a non-redemption agreement with one or more unaffiliated third parties pursuant to which the third parties have agreed not to redeem an aggregate of 400,000 shares of the company’s Class A common stock at its upcoming extension meeting.
In exchange for the foregoing commitments not to redeem the shares, the sponsor has agreed to transfer an aggregate of 100,000 shares of the Company’s Class B common stock to the third parties immediately following the completion of an initial business combination.
M3-Brigade II intends to hold its extension meeting on March 7 and hopes to gain shareholder approval to extend its deadline from March 8 to December 8. Additionally, the sponsor intends to enter into additional non-redemption agreements prior to the meeting.
In the event that the extension is approved, funds in the SPAC’s trust, including any interest earned, will not be used to pay for any excise tax liabilities with respect to any redemptions.
M3-Brigade II noted in the filed 8-K that today’s non-redemption agreements are not expected to increase the likelihood that the extension is approved, but it is expected to increase the amount of funds that remain in MBAC’s trust account following the meeting.
M3-Brigade II announced the pricing of its $400 million IPO in March 2021. It initially agreed to combine with Syniverse in a $2.8 billion deal in August 2021, but later terminated the deal in February 2022 citing market conditions and noting that redemptions would have made it unable to meet the deal’s minimum cash condition.
D. Boral ARC Acquisition II Corp. (NASDAQ:ARBCU) has filed for a $250 million SPAC to give underwriter D. Boral a second in-house SPAC to pursue deals with. The new SPAC offers investors a 1/2 warrant and an initial 18-month time frame to complete a deal. D. Boral II’s sponsor may automatically extend this once by...
Ribbon (NASDAQ:RIBB) has entered into a definitive agreement to combine with Japanese biotech firm DRC Medicine at a pro forma equity value of $422 million. Tokyo-based DRC Medicine manufactures reusable anti-bacterial and anti-allergen wearables and aims to go deeper into the medical device and pharmaceutical space. Transaction Overview Ribbon is expected to provide $50.4 million...
In June 2025, the SPAC market was marked by a notable rise in meeting delays, with adjournments and postponements playing a central role in extension activity, as sponsors navigated a more cautious market environment. Still, several SPACs secured shareholder approvals, and seven business combinations were completed during the month. At the same time, IPO issuance...
An In-Depth Look at SPAC Activity Through the Second Quarter & First Half 2025 Below is a summary of the first half of 2025 SPAC market. If you’d like a pdf copy, you can access the link HERE. Q2 kicked off in chaos. President Trump’s shifting and often contradictory tariff announcements sent markets reeling, driving...
At the SPAC of Dawn The market is set to be showered with new SPACs today as three more SPACs priced their IPOs overnight, bringing 2025’s total to 66, already surpassing the full-year total of 2024. After hours, Ribbon (NASDAQ:RIBB) also added a new SPAC deal to June’s tally just under the wire, bringing the...